Gastroenterology

Projects

Projects per year 2013 2019 2020 2021 2022 2023 2024 2030

• 3 Not started
• 29 Active
• 53 Finished

Projects per year

Search results

• Finished

  Consortium for Research expertise in Eating Disorders (CORED)

  Sharp, G. (Primary Chief Investigator (PCI)), Langiu, M. (Chief Investigator (CI)), Ramadas, A. (Chief Investigator (CI)), Yao, C. (Chief Investigator (CI)) & Stafrace, S. (Chief Investigator (CI))

  20/11/23 → 31/12/24

  Project: Research

• NHMRC Equipment Grant - UVITEC Alliance Q9 Advanced imager

  Shackleton, M. (Primary Chief Investigator (PCI)), Boussioutas, A. (Chief Investigator (CI)), Andrews, M. (Chief Investigator (CI)), Naranbhai, V. (Chief Investigator (CI)) & Kong, J. (Chief Investigator (CI))

  1/11/23 → 31/12/24

  Project: Research

• A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING)

  Burgell, R. (Primary Chief Investigator (PCI)) & Boussioutas, A. (Chief Investigator (CI))

  4/04/23 → 3/04/25

  Project: Research

• A three-part, double-blind, placebo-controlled, Phase I/Ib study of the safety, tolerability and pharmacokinetics of single and multiple ascending doses of IMU-856 in healthy volunteers and patients with celiac disease.

  Brown, G. (Primary Chief Investigator (PCI))

  20/09/22 → 1/06/24

  Project: Research

• HER2 testing in advanced gastric cancer – understanding and reducing variation in current practice to improve patient survival

  Ioannou, L. (Primary Chief Investigator (PCI)), Zalcberg, J. (Chief Investigator (CI)), Boussioutas, A. (Chief Investigator (CI)), Fox, S. B. (Chief Investigator (CI)), Duong, C. P. (Chief Investigator (CI)), Wong, R. (Chief Investigator (CI)), Chen, R. (Chief Investigator (CI)), Haydon, A. (Chief Investigator (CI)), Graco, M. (Chief Investigator (CI)), Saxon, S. (Associate Investigator (AI)), Ananda, S. (Associate Investigator (AI)), Tagkalidis, P. (Associate Investigator (AI)), Lipton, L. R. (Associate Investigator (AI)), Brown, S. B. (Associate Investigator (AI)), Aga, A. (Associate Investigator (AI)), Hair, C. (Associate Investigator (AI)) & Tawfik, B. (Associate Investigator (AI))

  4/04/22 → 7/04/25

  Project: Research

• The role of a low emulsifier diet in treating Crohn's disease

  Halmos, E. (Supervisor) & Fitzpatrick, J. W. (Primary Chief Investigator (PCI))

  1/02/22 → 24/04/24

  Project: Research

• A Phase 2a, Randomized, Blinded, Multicenter Study Investigating a Combination of AB-729 and VTP-300 in Virologically-Suppressed Chronic Hepatitis B Participants.

  Roberts, S. (Primary Chief Investigator (PCI))

  1/02/22 → 31/12/24

  Project: Research

• Atmo bar : Development of Atmo Cereal bars

  Gibson, P. (Primary Chief Investigator (PCI)), Muir, J. (Chief Investigator (CI)), Yao, C. (Chief Investigator (CI)) & So, D. (Chief Investigator (CI))

  18/10/21 → 17/10/22

  Project: Research

• Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial

  Roberts, S. (Primary Chief Investigator (PCI))

  9/09/21 → 31/12/24

  Project: Research

• RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

  Roberts, S. (Primary Chief Investigator (PCI))

  16/07/21 → 31/12/24

  Project: Research

• A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION AND MAINTENANCE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS

  Burgell, R. (Primary Chief Investigator (PCI)), Perananthan, V. (Primary Chief Investigator (PCI)) & Burgell, R. (Primary Chief Investigator (PCI))

  8/07/21 → 31/12/24

  Project: Research

• A Randomized Phase 2a, Multicenter, Open-Label, Multiple-Cohort Study Evaluating Regimens Containing Vebicorvir in Subjects with Chronic Hepatitis B Virus Infection

  Roberts, S. (Primary Chief Investigator (PCI)), Matthews, G. V. (Chief Investigator (CI)), Sasadeusz, J. (Chief Investigator (CI)), Chen, F. (Chief Investigator (CI)), Valaydon, Z. S. (Chief Investigator (CI)), George, J. (Chief Investigator (CI)), MacQuillan, G. (Chief Investigator (CI)), Thompson, A. J. (Chief Investigator (CI)) & Davison, S. (Chief Investigator (CI))

  12/05/21 → 31/12/22

  Project: Research

• Using dietary therapy to slow the progression of diabetic kidney disease

  Snelson, M. (Primary Chief Investigator (PCI)), Coughlan, M. (Chief Investigator (CI)), Ekinci, E. (Chief Investigator (CI)), Baqar, S. (Chief Investigator (CI)), Muir, J. (Chief Investigator (CI)) & Kellow, N. (Chief Investigator (CI))

  3/05/21 → 31/12/24

  Project: Research

• A Double-Blinded, randomized, Parallel-Group, PHASE 2 Study to investigate the Effect of RO7049665 on the time to relapse following steroid tapering in patients with Autoimmune Hepatitis

  Roberts, S. (Primary Chief Investigator (PCI)) & Jones, A. (Project Manager)

  1/03/21 → 31/12/24

  Project: Research

• The new face of dietary therapy in pouchitis: targeting pathogenic factors from the pouch microbiota

  Gibson, P. (Primary Chief Investigator (PCI)), Yao, C. (Chief Investigator (CI)) & Ardalan, Z. S. M. (Chief Investigator (CI))

  25/01/21 → 31/12/21

  Project: Research

• Randomized, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of EP547 in Healthy Subjects with Cholestatic or Uremic Pruritis.

  Roberts, S. (Primary Chief Investigator (PCI)) & Kerr, P. (Chief Investigator (CI))

  1/12/20 → 31/12/22

  Project: Research

• Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double- blind, Placebo-Controlled Study of APT-1011, with an open-label extension, in Adult Subjects with Eosinophilic Esophagitis

  Burgell, R. (Primary Chief Investigator (PCI))

  1/11/20 → 31/12/24

  Project: Research

• A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN 74809 in participants with primary sclerosing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC).

  Roberts, S. (Primary Chief Investigator (PCI)), Adams, L. A. (Chief Investigator (CI)), George, J. (Chief Investigator (CI)), Strasser, S. I. (Chief Investigator (CI)), Thompson, A. J. (Chief Investigator (CI)) & Lynch, K. D. (Chief Investigator (CI))

  1/10/20 → 1/11/23

  Project: Research

• A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection.

  Roberts, S. (Primary Chief Investigator (PCI)) & Mitchell, J. L. (Project Manager)

  15/08/20 → 15/08/22

  Project: Research

• A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012).

  Roberts, S. (Primary Chief Investigator (PCI)) & Lewis, P. (Project Manager)

  5/06/20 → 31/12/23

  Project: Research

• Creating an evidence base for clinical care: A randomized controlled study examining the efficacy of the low FODMAP diet for the relief of gastrointestinal symptoms in endometriosis.

  Muir, J. (Primary Chief Investigator (PCI)), Burgell, R. (Chief Investigator (CI)), Varney, J. (Chief Investigator (CI)), Moore, J. (Chief Investigator (CI)), Morrison, M. (Chief Investigator (CI)) & Fisher, J. (Chief Investigator (CI))

  1/06/20 → 1/06/20

  Project: Research

• The 4-SURE (4-Sulfide-Reducing) project: pioneering a new diet paradigm in the management of ulcerative colitis and pouchitis

  Yao, C. (Primary Chief Investigator (PCI))

  Crohn's and Colitis Australia

  24/02/20 → 24/02/24

  Project: Research

• Evaluation of Efficacy, Safety and Tolerability of NGM282 (aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE4)

  Roberts, S. (Primary Chief Investigator (PCI)) & Jones, A. (Project Manager)

  14/02/20 → 31/12/22

  Project: Research

• Prevalence of sucrase-isomaltase genetic hypomorphic variants in patients with irritable bowel syndrome in Australia

  Mitchell, H. (Chief Investigator (CI)), Garg, M. (Chief Investigator (CI)), Porter, J. (Chief Investigator (CI)), Gibson, P. (Chief Investigator (CI)) & Barrett, J. (Chief Investigator (CI))

  1/01/20 → 31/12/20

  Project: Research

• A Phase 2, Randomized, Double-blinded, Placebo-controlled, Multicenter, Dose-finding Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

  Roberts, S. (Primary Chief Investigator (PCI))

  19/12/19 → 31/12/24

  Project: Research

• RECIPE: Randomised controlled trial (RCT) of ROTEM-guided blood component administration versus standard of care in patients with cirrhosis and coagulopathy undergoing invasive procedures.

  Majeed, A. (Primary Chief Investigator (PCI)), Janko, N. E. (Chief Investigator (CI)), Roberts, S. (Chief Investigator (CI)), Kemp, W. (Chief Investigator (CI)), Nandurkar, H. (Chief Investigator (CI)) & Gow, P. J. (Chief Investigator (CI))

  5/12/19 → 20/12/24

  Project: Research

• Comparison of Regional Transit Measurement for the Atmo Capsule with those of a Gold Standard (Smart Pill)

  Gibson, P. (Primary Chief Investigator (PCI)), Halmos, E. (Chief Investigator (CI)) & Yao, C. (Chief Investigator (CI))

  Atmo Biosciences Limited

  1/12/19 → 1/08/21

  Project: Research

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients with Primary Sclerosing Cholangitis (PSC)

  Roberts, S. (Primary Chief Investigator (PCI))

  22/11/19 → 31/12/21

  Project: Research

• A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation

  Roberts, S. (Primary Chief Investigator (PCI)) & Lewis, P. (Project Manager)

  8/11/19 → 30/06/23

  Project: Research

• Centre for Research Excellence in Digestive Health

  Talley, N. J. (Primary Chief Investigator (PCI)), Holtmann, G. (Chief Investigator (CI)), Walker, M. M. (Chief Investigator (CI)), Jones, M. (Chief Investigator (CI)), Morrison, M. (Chief Investigator (CI)), Keely, S. (Chief Investigator (CI)), Gibson, P. (Chief Investigator (CI)), Chan, S. (Chief Investigator (CI)), Tack, J. (Chief Investigator (CI)) & Coombes, J. S. (Chief Investigator (CI))

  1/11/19 → 31/10/24

  Project: Research

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis

  Roberts, S. (Primary Chief Investigator (PCI)) & Lewis, P. (Project Manager)

  30/10/19 → 31/12/21

  Project: Research

• A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation. Clinical study No. MGL-3196-11.

  Roberts, S. (Primary Chief Investigator (PCI))

  24/10/19 → 31/12/24

  Project: Research

• A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma.

  Roberts, S. (Primary Chief Investigator (PCI)), Lewis, P. (Project Manager), George, J. (Chief Investigator (CI)), Zekry, A. (Chief Investigator (CI)), O’Beirne, J. (Chief Investigator (CI)), Tse, E. (Chief Investigator (CI)), McLachlan, S. A. (Chief Investigator (CI)), Eastgate, M. (Chief Investigator (CI)), Ananda, S. (Chief Investigator (CI)) & Davison, S. (Chief Investigator (CI))

  24/09/19 → 30/09/23

  Project: Research

• A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis.

  Burgell, R. (Primary Chief Investigator (PCI)) & Hogg, J. (Project Manager)

  9/09/19 → 31/12/24

  Project: Research

• A prospective, cross-sectional, multi-centre study to evaluate the clinical performance of the ColoSTAT In Vitro Diagnostic for the detection and evaluation of Biomarkers associated with the occurrence of colorectal cancer.

  Brown, G. (Primary Chief Investigator (PCI))

  21/06/19 → 31/07/20

  Project: Research

• A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GS-4224 in Healthy Volunteers and Subjects with the Chronic Hepatitis B (CHB) Virus

  Roberts, S. (Primary Chief Investigator (PCI)) & Jones, A. (Project Manager)

  19/06/19 → 31/05/21

  Project: Research

• A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of Single and Multiple Doses of ABI-H2158 in Healthy Volunteers; and the Multiple-Ascending Dose Pharmacokinetics and Pharmacodynamics in Patients with Chronic Hepatitis B Infection.

  Roberts, S. (Primary Chief Investigator (PCI)) & Mitchell, J. L. (Project Manager)

  29/05/19 → 30/09/19

  Project: Research

• A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma who are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2).

  Roberts, S. (Primary Chief Investigator (PCI))

  17/05/19 → 31/05/23

  Project: Research

• An Open-Label Study to Assess The Efficacy and Safety of LM011 In Subjects Diagnosed With Non-Alcoholic Steatohepatitis (NASH).

  Roberts, S. (Primary Chief Investigator (PCI))

  16/04/19 → 31/12/19

  Project: Research

• The impact of day-time and night-time endurance exercise on gastrointestinal integrity, functional responses, symptoms, and systemic endotoxin and cytokine profiles - A laboratory controlled mechanistic exploration of circadian variation influences in ultra-endurance athletes.

  Da Costa, R. (Primary Chief Investigator (PCI)), Gaskell, S. (Project Manager), Muir, J. (Associate Investigator (AI)) & Burgell, R. (Associate Investigator (AI))

  4/02/19 → 31/12/19

  Project: Research

• A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1).

  Roberts, S. (Primary Chief Investigator (PCI)) & Lewis, P. (Project Manager)

  24/01/19 → 30/04/23

  Project: Research

• Ingestible capsules for sensing gut metabolites

  Kalantar-zadeh, K. (Primary Chief Investigator (PCI)), Gibson, P. (Chief Investigator (CI)), Muir, J. (Chief Investigator (CI)), McSweeney, C. S. (Chief Investigator (CI)), Hebblewhite, M. (Associate Investigator (AI)) & Berean, K. J. (Associate Investigator (AI))

  1/01/19 → 1/01/21

  Project: Research

• A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge.

  Brown, G. (Primary Chief Investigator (PCI)) & Secomb, R. (Project Manager)

  5/11/18 → 31/12/19

  Project: Research

• Open Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 +/- ribavirin (RBV) in the treatment of Hepatitis C G1 and 4, in patients either eligible for liver transplant (HCC) or curative therapy or non-eligible for curative therapy but clinically stable disease post local resection, embolization or ablative therapy: HATCHeT Study - HepATocellular Cancer Hcv Therapy Study.

  Kemp, W. (Primary Chief Investigator (PCI)) & Mitchell, J. (Project Manager)

  7/08/18 → 7/08/23

  Project: Research

• Comparison of the performance of SB2‐Infliximab with originator Infliximab in the measurement of concentrations in serum

  Gibson, P. (Primary Chief Investigator (PCI))

  23/05/18 → 23/06/18

  Project: Research

• FODMAP: Changing therapeutic paradigms for intestinal health: Diet as a therapeutic strategy in Gastroenterology.

  Muir, J. (Primary Chief Investigator (PCI))

  1/01/18 → 31/12/22

  Project: Research

• Sugar cane fibre - understanding of efficacy and value creation

  Muir, J. (Primary Chief Investigator (PCI)) & Gibson, P. (Chief Investigator (CI))

  1/09/17 → 31/08/20

  Project: Research

• The role of a low emulsifier diet in the treatment of inflammatory bowel disease

  Halmos, E. (Primary Chief Investigator (PCI))

  1/07/17 → 30/06/18

  Project: Research

• Community Approach Targeting Cirrhosis and Hepatocellular carcinoma (CATCH) in patients living with chronic viral hepatitis

  Lubel, J. (Primary Chief Investigator (PCI))

  17/04/17 → 16/04/19

  Project: Research

• Investigating the 'digestibility' of soymilk drinks: Comparison of low (So Good) and high FODMAP soy drinks on the production of breath hydrogen and gastrointestinal symptoms in human volunteers

  Muir, J. (Primary Chief Investigator (PCI)) & Gibson, P. (Chief Investigator (CI))

  16/06/15 → 16/09/16

  Project: Research